Clinical Advisor

AACE Updates Guidance on Obesity, Adiposity-Based Chronic Disease

The AACE consensus statement emphasizes improvement of overall health in addition to weight reduction among adults with obesity and adiposity-based chronic disease.

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

A year after stopping taking weight-loss drugs such as Ozempic and Wegovy, people regain—on average—60% of their lost weight. But beyond this, their regained weight plateaus, with individuals managing ...
Forbes

Why Genetic Weight Loss Is Succeeding Where Diets And GPL-1 Drugs Fail

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Dr. Phyllis Pobee, founder of GeneLean360° is part of a growing shift toward personalized ...
The Manila Times

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achie…

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of ...